Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort ascending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Stalevo | Carbidopa, levodopa and entacapone | Parkinsons Disease | List in a similar manner | Complete | ||
Thelin | Sitaxsentan sodium | Pulmonary arterial hypertension (WHO class II and III) | Do not list | Complete | ||
Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | ||
Relistor | Methylnaltrexone bromide | Constipation, Opioid-induced | Do not list | Complete | ||
Celsentri | Maraviroc | HIV | List with clinical criteria and/or conditions | Complete | ||
Omnaris | Ciclesonide nasal spray | Allergic Rhinitis (seasonal and perennial) | Do not list | Complete | ||
Pradaxa | Dabigatran etexilate | Thromboembolism (venous), prevention | Do not list | Complete | ||
Xyrem | Sodium oxybate | Narcolepsy | Do not list | Complete | ||
Volibris | Ambrisentan | Pulmonary arterial hypertension (WHO class II and III) | List with clinical criteria and/or conditions | Complete | ||
Campral | Acamprosate calcium | Alcohol Abstinence | N/A | Complete |